Navigation Links
Kendle to Present at UBS Global Life Sciences Conference
Date:9/16/2009

CINCINNATI, Sept. 16 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the Company will participate in the upcoming UBS Global Life Sciences Conference on Sept. 21, 2009, at the Grand Hyatt New York Hotel in New York City.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

Kendle's formal presentation will be given by Chairman and Chief Executive Officer Candace Kendle, PharmD, at 12:30 p.m. Eastern Time.

The presentation will be Webcast and may be accessed at www.kendle.com in the "Investors Events & Presentations" section or at http://cc.talkpoint.com/ubsx001/092109a_ke/?entity=74_NFDSOWW.

Slides will be available by 10 a.m. on the day of the presentation at www.kendle.com in the "Investors Events & Presentations" section.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery
'/>"/>

SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kendle to Present at Robert Baird 2009 Health Care Conference
2. Kendle Realigns C-Suite Leadership to Drive Increased Innovation, Productivity and Organizational Efficiency
3. Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
4. Kendle Names Jarrod Pontius Chief Legal Officer
5. Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
6. Kendle Announces First Quarter 2009 Results
7. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
8. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
9. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
10. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
11. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Mass. , April 16, 2015  EMD ... Merck KGaA, Darmstadt, Germany , ... Vice President, Head of Global Clinical Development.  Dr. ... expertise, including experience in Oncology and Immunology. She ... ability, having served as a Vice President in ...
(Date:4/16/2015)... and MENLO PARK, Calif. ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical ... in new orphan drug indications, today announced that the ... as a clinical trial site for the ongoing, multicenter ... glioblastoma multiforme (GBM), the most common and deadly form ...
(Date:4/16/2015)... , April 16, 2015  Northwest Biotherapeutics, Inc. ... company developing non-toxic DCVax® personalized immune therapies for ... in the Loncar Cancer Immunotherapy Index (LCINDX), a ... track the immunotherapy field within the biotechnology space.  ... "the top 25 companies" in the immunotherapy space, ...
(Date:4/16/2015)... Modality Solutions, a company that delivers ... industries, is pleased to announce its President, Gary ... Cold Chain IQ - Temperature Control Logistics and ... Global Cold Chain Connections, is dedicated to sharing ... pharmaceutical and healthcare supply chains. , Cold ...
Breaking Biology Technology:Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
... Scientific, a leading medical device/biopharmaceutical company located in Santa ... IS CHO-CD XP(TM) Culture System to their cell culture ... a set of chemically-defined*, serum-free, and animal component free ... growth and production for recombinant CHO cell lines. ...
... for BiofuelKINGSTON, ON, March 6 /PRNewswire/ - Performance ... and biofuel biotechnology development and Sustainable Development Technology ... project led by PPI will be receiving up ... will be used to advance its trait technologies ...
... with Major Biopharmaceutical CompanyBELGIUM, Wis., March 6 ... to announce that its subsidiary, Modular Process Constructors ... to better reflect its vision, and announces that ... major global biopharmaceutical and consumer health company. The ...
Cached Biology Technology:Irvine Scientific Launches IS CHO-CD XP(TM) 2Canadian Government Announces Funding for Leading Biotechnology Firm's Project 2Canadian Government Announces Funding for Leading Biotechnology Firm's Project 3Mach One Subsidiary Modular Process Constructors LLC Changes Name to MPS BioPharm to Better Reflect its Vision 2
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
(Date:3/12/2015)... Va. , March 12, 2015 IriTech, ... and a member of the Texas Instruments Design Network, ... Naidu has demonstrated its IriShield USB MK2120U device ... scanning facility for pension distribution. The ... assembled to be marketed in India ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3
... design of vaccines is rapidly expanding their use, safety, and ... of OMICS sciences for global health and vaccine design is ... special issue of OMICS: A Journal of Integrative Biology ... Inc . The issue is available free online . ...
... promiscuous in order to screen out sperm from genetically incompatible ... Anglia (UEA). Published tomorrow in the journal ... of why females in most species mate with multiple males ... and promiscuity can carry fatal risks for the female. ...
... announced that Prof. Madhav Marathe has been selected as ... George A. Michael Distinguished Scholar is an annual award ... time carrying out research at the Institute for Scientific ... intent of the scholarship is to foster long-term collaboration ...
Cached Biology News:21st century vaccines -- innovation in design and rational use 221st century vaccines -- innovation in design and rational use 3Female promiscuity can rescue populations from harmful effects of inbreeding 2Female promiscuity can rescue populations from harmful effects of inbreeding 3
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
Biology Products: